AZD2066 Neuropathic Pain - Mechanical Hypersensitivity

• Status: Terminated
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate if 28 days of treatment with AZD2066 compared to placebo can relieve the pain arising from the nervous system when the patients are touched by something that should not cause pain or have severe pain when they are touched by something that should only cause a little pain.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Quintiles, Inc.

Criteria

Inclusion Criteria:

• Provision of informed consent prior to any study specific procedures.

• Male or non-fertile females

• Painful symptoms due to neuropathic pain for a period of 3 months to 5 years, associated with mechanical allodynia and/or punctate hyperalgesia.

Exclusion Criteria:

• Other pain that may confound assessment of neuropathic pain.

• Diagnosis of any severe neurological disease.

• History of significant psychiatric disease/condition and/or history of psychotic disorders among first degree relatives.